US Influenza Antivirals Market Industry Trends and Forecast to 2034: Segmented by (Drug, Buyer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$536.6 MnPlaceholder estimate
Estimate 2025$548.9 Mn42.3% of the global market
Projected 2034$673.6 Mn 22.7%Adds $124.7 Mn over 9 forecast years
CAGR 2025–20342.3%Faster than 11% of 180 Pharmaceuticals markets here
Key players5
US is 42.29% of the global market.
In North America, the largest is US (this report) at $548.9 Mn.
93 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Influenza Antivirals Market Analysis Executive Summary
Influenza antivirals treat flu and shorten illness if started early, and are stockpiled for pandemics.
Key segments of the influenza Antivirals market include drug (Oseltamivir, Baloxavir and Zanamivir) and buyer (Retail, Hospitals and Government Stockpiles).
US Influenza Antivirals market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Influenza Antivirals Market Dynamics
Market Growth Drivers
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the influenza Antivirals market.
Opportunity
New vaccines, rapid tests and public-private funding for neglected diseases give the influenza Antivirals market room to grow, especially in Asia, Africa and Latin America.
Market Restraints
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the influenza Antivirals market.
Competitive Landscape for Influenza Antivirals Market in US
The influenza Antivirals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Influenza Antivirals Market in US
Influenza Antivirals in the US: rules, payment and research
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 93 studies on Influenza Antivirals that are recruiting, active or about to start in the US.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for influenza Antivirals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug
4.2 By Buyer
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Roche
7.2 Shionogi
7.3 GSK
7.4 BioCryst Pharmaceuticals
7.5 Cipla
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The influenza Antivirals market can be segmented based on various criteria, including drug, buyer and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Source: WHO Prequalification, Vaccines, tests and medicines on the WHO prequalified lists that match this market. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Influenza Antivirals right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Influenza Antivirals in context
The US compared
Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
How big is the Influenza Antivirals market in the US?
Placeholder estimate: about $548.9 Mn in 2025, rising to about $673.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Influenza Antivirals market in the US growing?
Placeholder estimate: about 2.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Influenza Antivirals market report cover?
The report splits the market by drug (Oseltamivir, Baloxavir, Zanamivir, Peramivir), buyer (Retail, Hospitals, Government Stockpiles) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Influenza Antivirals market?
Key players include Roche, Shionogi, GSK PLC, BioCryst Pharmaceuticals and Cipla Inc..
What is driving the Influenza Antivirals market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the influenza Antivirals market.
Who regulates Influenza Antivirals in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Influenza Antivirals are running in the US?
93 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Influenza Antivirals?
PubMed lists 47 papers on Influenza Antivirals added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US 
Canada
China
Japan
Germany
UK
Italy
France
Brazil
Ecuador
Spain
India
Saudi Arabia
Mexico
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Malaysia
Hong Kong
Singapore
Thailand
Kenya
Sanofi
Aurobindo Pharma